Vistra Corp.
VST - NYSE - $160.38 ▼ -%0.29
-
Earnings Thu 7 May
Note: this preview was published before the 2026-05-07 earnings report. Results have since been released — verify against the latest filings.

Vistra opens the
books on Thursday evening.

6 analysts' median target is $225[FMP target], stock is $160, +40.0% upside potential. After Q4 +-76.5% EPS beat[FMP earnings], the stock moved -1.7%.

summary below
Quick Take - in 40 seconds
C+
BUY Council 5/6 - Moonshot 33

C+ = MoonshotScore 33[9-pillar formula] + Council 5/6[6-lens rule]. Form 4: 0 transactions[FMP Form 4].

Q4 consensus: revenue $5.2B[FMP est], EPS $1.32[FMP est]. 0 consecutive quarters of beat[FMP earnings].

$1.32 EPS Estimate Last year $0.54 - -242% YoY YoY
0 Beat Streak Expectations beaten consecutively for the last 0 quarters

Q4 EPS +-76.5% beat[FMP] but the stock -1.7% D+1[FMP D+1]. Kristopher Moldovan promised $1.5B CapEx + a sequential decline in Q4 during the Q4 earnings call[Kristopher Moldovan capex transcript].

Watchlist

6 metrics stand out this quarter.

2026 Expectation / Guide

Cash Generation Outlook

cash_generation_outlook

Vistra projects to generate more than $10 billion of cash through year-end 2027.

"Based on our expectations for 2026 and our previously communicated range of midpoint opportunities for 2027 as well as the expected contribution in 2026 and 2027 from the Meta PPAs and the closing of the Cogentrix acquisition, we project to generate more than $10 billion of cash through year-end 2027."

- Kristopher Moldovan, Executive Vice President and Chief Financial Officer - Q4 FY25 Earnings Call - February 26, 2026
2026 Expectation / Guide

Load Growth Outlook

load_growth_outlook

Vistra expects calendar years 2026 and 2027 to continue to show growth, which would mark the first 4-year period of sustained growth since the 4-year period ending 2007.

"We expect calendar years 2026 and 2027 to continue to show growth, which would mark the first 4-year period of sustained growth since the 4-year period ending 2007."

- James Burke, President and Chief Executive Officer - Q4 FY25 Earnings Call - February 26, 2026
$730 Investor Focus

Cogentrix Acquisition Accretion

cogentrix_acquisition_accretion

The Cogentrix acquisition is expected to deliver mid-single-digit adjusted free cash flow before growth per share accretion in 2027, with a high single-digit accretion on average over the '27 to '29 period.

"From a financial perspective, we view the purchase price as attractive at approximately $730 per kilowatt of capacity, net of expected tax benefits, and we expect the transaction to deliver mid-single-digit adjusted free cash flow before growth per share accretion in 2027, with a high single-digit accretion on average over the '27 to '29 period."

- James Burke, President and Chief Executive Officer - Q4 FY25 Earnings Call - February 26, 2026
2021 Investor Focus

Share Repurchase Program

share_repurchase_program

Since initiating the program in November 2021, we have retired approximately 167 million shares at an average cost below $36 per share, delivering over $20 billion of value for our long-term shareholders.

"Since initiating the program in November 2021, we have retired approximately 167 million shares at an average cost below $36 per share, delivering over $20 billion of value for our long-term shareholders."

- Kristopher Moldovan, Executive Vice President and Chief Financial Officer - Q4 FY25 Earnings Call - February 26, 2026
$5.9 Investor Focus

Record Financial Performance

record_financial_performance

Vistra achieved record financial performance in 2025, delivering approximately $5.9 billion of adjusted EBITDA and approximately $3.6 billion of adjusted free cash flow before growth.

"For the full year, we achieved approximately $5.9 billion of adjusted EBITDA and approximately $3.6 billion of adjusted free cash flow before growth, both meaningfully above the midpoint of our original guidance ranges."

- James Burke, President and Chief Executive Officer - Q4 FY25 Earnings Call - February 26, 2026
25% Investor Focus

Nuclear Ppa Impact

nuclear_ppa_impact

Upon achieving full ramp of all the nuclear agreements, we see a pathway to nearly 25% adjusted free cash flow before growth accretion on an annual basis.

"Upon achieving full ramp of all the nuclear agreements, we see a pathway to nearly 25% adjusted free cash flow before growth accretion on an annual basis."

- James Burke, President and Chief Executive Officer - Q4 FY25 Earnings Call - February 26, 2026

Stock Expert AI - Methodology

Do our 9 pillars, 7 perspectives, and Munger lens point in the same direction?

Council Score 5 / 6 Bullish

6 investor frameworks. 5 bullish (Ray Dalio, Ken Griffin, Klarman, Buffett, Munger), 0 bearish (none), 1 neutral (Jim Simons).

How is it calculated? ->
Ray Dalio macro - target upside +40.0%
Ken Griffin flow - 50d MA above
Jim Simons quant - RSI 52
Klarman value - target upside +40.0%
Buffett quality - ROE score 5/5
Munger valuation - target upside +40.0%
Munger's Mindset character & balance sheet lens
Undervalued

Quality business, discounted price.

How is it calculated? ->
Financial HealthWeak
Margin of SafetyStrong
Interest CoverageAdequate
ROIC vs WACCHealthy
Technical Levels - Pre-earnings positioning

What levels is the stock being tested at?

RSI(14)
51.7 RSI 51.7 balanced, 50d above
MACD
+0.40 price above 50d - support positive
50d MA
$160 stock 0.4% above - short-term support
200d MA
$178 stock 9.7% below - long-term pressure
Volume (10d)
-9% decrease - low participation
Resistance
$225
Analyst median target - upgrade trigger if broken
Current
$160
Pre-earnings position
Support
$151
Invalidation - close below this is a technical breakdown
Pattern
Range
$151-$225 band - earnings breakout/breakdown trigger

Past Performance

Vistra's last 8 quarters: 0 consecutive beats.

MISS
Q1 FY25
$-0.93 vs $0.54 est - -3.7%
MISS
Q2 FY25
$0.81 vs $0.88 est - +2.4%
MISS
Q3 FY25
$1.75 vs $2.08 est - +3.5%
MISS
Q4 FY25
$0.54 vs $2.31 est - -1.7%

Q4 (February 26, 2026): EPS $0.54 vs $2.31 est[FMP], +-76.5% beat. D+1 movement: -1.7%[FMP D+1]. Decline despite beat - market reacted to guidance, not numbers.

Three scenarios: what could happen?

EPS < $1.28 (no guidance)

Q4: EPS $0.54 vs $2.31 beat[FMP], stock -1.7% D+1[FMP].

Backlog concentration

No RPO/backlog concentration disclosed in Q4 earnings call.

CapEx shock

Q4 CapEx $1.5B[FMP cashflow]. Q4 op margin -74.8%[FMP op margin] - this level in Q4 is sensitive to CapEx revision risk.

Framework - Position discipline

After the data arrives: 3 scenarios, 3 windows

Not advice - a structural framework for earnings night. Decision discipline is yours.

Scenario A - Beat
Q4 EPS > $1.32 + CapEx discipline
Threshold: EPS > $1.32[FMP est].
Target: Break above median target $225[FMP target]; high target $293[FMP] upper bound.
Scenario B - In-Line
EPS approx $1.32 + CapEx < $1.5B
Threshold: EPS approx $1.32[FMP est], Q4 CapEx < $1.5B[FMP].
Target: Consolidation in the band between current $160[FMP] and median $225[FMP].
Scenario C - Miss
EPS < $1.28 or CapEx >= $1.5B
Threshold: EPS < $1.28[FMP estx0.97].
Target: Current $160 below SMA200 $178[FMP], if rejection continues, $151[derived] support activates.
Sizing
Earnings volatility -> max portfolio 1-2%. Waiting for earnings is not a gamble, it's a position entrustment.
Timing
IV crush within 24 hours post-earnings. Waiting for premium decay makes options preferable to spot.
Staging
Don't go all-in at once, divide into 3: initial reaction, 24 hours later, after Friday's close.

Market Outlook

What do 6 analysts say?

Wall Street Consensus
$225
12-month median target price (+40.0% upside potential)
19
BUY
0
HOLD
1
SELL
Risk Management
$151
Invalidation level - critical support threshold
$160 - 50-day MA (above, +0.4%)
$178 - 200-day MA (below, -9.7%)
IV Crush risk (sudden drop in inflated option premiums before earnings): Option premiums are inflated before earnings.
Verdict - VST Q4 FY26
C+

You read it in 5 minutes. When the numbers come out on Thursday evening - you know what you're looking at.

Data arrives at night. The framework is ready now.

Data arrives on Thursday evening. The framework is ready on this page: Q4 EPS threshold $1.32[FMP], CapEx threshold "below $1.5B"[Kristopher Moldovan]. Two anchors, three scenarios.

Comparison Stock Expert AI Pro $24/month ($240/year), 77% cheaper than the total of three earnings-tracking tools ($1,059/year -> $240/year).

3 subscriptions. 1 platform.

Seeking Alpha $299/yr - analyst opinions + earnings coverage TipRanks $360/yr - Smart Score (1-10) + analyst consensus + insider trades Trendspider $400/yr - AI pattern detection + automated TA + multi-timeframe alerts

Prices as of April 2026. Sources: seekingalpha.com/subscriptions - tipranks.com/pricing - trendspider.com/pricing

Stock Expert AI Pro: $24/month ($240/year). Council 7-lens analysis + MoonshotScore 9-pillar + Insider tracker + Technical levels - all in one platform, for every stock.

Educational tool, not investment advice. Past performance does not guarantee future results.

Calendar

Catalyst Calendar - 90-day forward look

May 7, 2026EARNINGSQ4 FY26 results (after market close) + earnings call
May 8, 2026PRICEFirst trading day after earnings - 200dMA test + IV crush
Jun 21, 2026FILING10-Q deadline - segment breakdown + RPO detail (SEC rule: quarter-end + 45 days)
~Aug 7, 2026EARNINGSQ1 FY27 (next quarter, date not yet scheduled in FMP)

DATA GAP: Events not in the FMP /stable/calendar feed - Investor day, analyst day, product launches, regulatory dates. These require company IR page scraping or manual calendar entry.

Frequently Asked Questions

What does the VST earnings preview cover?

This VST (VST) earnings preview covers the analyst consensus, key catalysts, and what to watch on the earnings call.

What should investors watch for in VST earnings?

Consensus EPS, revenue guidance, segment growth rates, and the tone of management commentary — the full breakdown with sources is on this page.